– CANADA, Vancouver – Bright Minds Biosciences (CSE: DRUG |OTC: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, today announced the appointment of Dr. Emer Lahey, Ph.D., MBA to its Board of Directors.
The company also announced the addition of Dr. Tom Lategan, Ph.D., VP of Regulatory Affairs, to its leadership team to manage regulatory and medical affairs.
“We are pleased to welcome Dr. Emer Leahy to the Bright Minds Biosciences Board. Her deep experience and track record of success in business development for pharmaceutical and biotechnology companies will help guide our drug development plans.” said CEO, Ian McDonald.
He continued: “We are also excited about the addition of Dr. Tom Lategan, whose extensive background in regulatory affairs will be an important asset to our team. We look forward to their insights as we continue to advance our programs to bring improved and targeted therapeutics to the patients who can benefit.”
About Dr. Emer Leahy
Emer Leahy, Ph.D., MBA, has over 30 years of experience in drug discovery, as well as clinical and business development for pharmaceutical and biotechnology companies. Dr. Leahy brings a wealth of knowledge in technology assessment, licensing, mergers and acquisitions, and strategic planning. Currently, Dr. Leahy serves as the CEO of PsychoGenics, Inc., a profitable preclinical CNS service company, and PGI Drug Discovery, LLC, a company engaged in psychiatric drug discovery. Previously, she served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization, and currently serves on the Board of Directors of Intensity Therapeutics, the Business Review Board for the Alzheimer’s Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She received her PhD in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University.
About Dr. Tom Lategan
Tom Lategan, Ph.D., has more than 20 years of experience in the pharmaceutical industry, across large-capitalization and start-up companies. Most recently, Dr. Lategan served as the Vice President of Regulatory Affairs for Banner Life Sciences. Prior to that, he served as the Vice President of Regulatory Affairs and Head of Clinical Operations at NeurAxon, Inc. He previously held positions of increasing responsibility in regulatory and medical affairs with Actelion, The Medicines Company and Hoffman-La Roche.
He received a D.Phil from Oxford University and a B.Sc. in pharmacology from Aberdeen University in Scotland.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.
For more information : https://brightmindsbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.